Prestayko Cisplatin

Current Status and New Developments
1. Auflage 2013
ISBN: 978-1-4832-8900-7
Verlag: Elsevier Science & Techn.
Format: EPUB
Kopierschutz: 6 - ePub Watermark

E-Book, Englisch, 544 Seiten

Cisplatin: Current Status and New Developments is a collection of papers presented at a symposium sponsored by the University of Alabama in Birmingham Comprehensive Cancer Center and the Bristol Laboratories in Syracuse, ?ew York, and held on September 27-28, 1979, in Atlanta, Georgia. The symposium provided a forum for assessing developments with regards to cisplatin as an anticancer drug, with emphasis on its clinical application in a wide variety of adult and pediatric malignancies as well as the mechanism by which the drug appears to cause tumor cell death. Comprised of 39 chapters, this book begins with a preclinical overview of cisplatin, focusing on its mechanism of action, pharmacology, antitumor activity, analogs, and toxicity. The discussion then turns to the effects of cisplatin on DNA and the possible relationships to cytotoxicity and mutagenicity in mammalian cells; lethal activity of platinum compounds in combination with pyrimidine derivatives; and ultrastructural effects of cisplatin. Subsequent chapters focus on the rationale of combination chemotherapy; toxic side effects of platinum analogs; radiopharmacokinetics of cisplatin; and the use of cisplatin for the treatment of malignancies such as ovarian cancer and advanced adenocarcinoma of the prostate. This monograph will be useful to oncologists and pharmacologists.

Autoren/Hrsg.

Prestayko, Archie W.

Leseproben

CONTRIBUTORS

Numbers in parentheses indicate the pages on which authors’ contributions begin.

SURINDER K. AGGARWAL(79),     Department of Zoology, Michigan State University, East Lansing, Michigan 48824

DAVID S. ALBERTS(393),     Section of Hematology-Oncology, Department of Internal Medicine, College of Medicine, University of Arizona, Tucson, Arizona 85724

SUSAN T. ARNOLD(237),     Laboratory of Toxicology, Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland 20205

LAURENCE H. BAKER(403),     Professor of Oncology, Wayne State University, Detroit, Michigan 48202

BARTHEL BARLOGIE(37),     Department of Developmental Therapeutics, The University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, 6723 Bertner Drive, Houston, Texas 77025

ROBERT S. BENJAMIN(495),     Department of Developmental Therapeutics, M. D. Anderson Hospital and Tumor Institute, University of Texas System Cancer Center, Houston, Texas 77030

JOHN-PIERRE BERGERAT(37),     Clinique des Maladies du Sang, Hospices civils de Strasbourg, 1 place de l’Hopital, 67000 Strasbourg, France

RAKESH BHUTANI(431),     Section of Medical Oncology, Department of Internal Medicine, Veterans Administration Medical Center, Boston, Massachusetts 02130

WERNER C. BIERBAUM(329),     Universitatsklinikum der Gesamthochschule Innere Klinik and Poliklinik (Tumorforschung), 4300 Essen 1, Hufelandstrasse 55, Federal Republic of Germany

JOHN BLESSING(411),     Gynecologic Oncology Group Statistical Office, Roswell Park Memorial Institute, 666 Elm Street, Buffalo, New York 14203

WILLIAM T. BRADNER(171, 227),     Antitumor Biology Department, Bristol Laboratories, Division of Bristol-Myers Company, Syracuse, New York 13201

HOWARD W. BRUCKNER(383),     Department of Neoplastic Diseases, Mount Sinai School of Medicine of the City University of New York, Fifth Avenue and East 100 Street, New York, New York 10029

JOSEPH H. BURCHENAL(113),     Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021

DIONISIO B. CALVO III(495),     Department of Developmental Therapeutics, M. D. Anderson Hospital and Tumor Institute, University of Texas System Cancer Center, Houston, Texas 77030

BRENDA CAPARROS(465),     Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021

STEPHEN K. CARTER(511),     Northern California Cancer Program, P. O. Box 10144, Palo Alto, California 94303

SYLVIA CLARKE(193),     Department of Biochemical Pharmacology, Institute of Cancer Research, Belmont, Surrey, England

MICHAEL J. CLEARE(149),     Chemical Operations Research, Johnson Matthey Research Centre, Blounts Court, Sonning Common, Reading, Berkshire, England

HUGH McD. CLINK(193),     Department of Haematology, Royal Marsden Hospital, Belmont, Surrey, England

CARMEL J. COHEN(383),     Department of Neoplastic Diseases, Mount Sinai School of Medicine of the City University of New York, Fifth Avenue and East 100 Street, New York, New York 10029

ROBERT L. COMIS(485),     Chief, Section of Oncology, SUNY Upstate Medical Center, Syracuse, New York 13210

PETER CORRY(37),     Department of Physics, The University of Texas System Cancer Center, M. D. Anderson Hospital, 6723 Bertner Drive, Houston, Texas 77025

STANLEY T. CROOKE(213, 249),,     Bristol Laboratories, Department of Research and Development, Syracuse, New York 13201; Department of Pharmacology, Baylor College of Medicine, Houston, Texas 77025; Department of Pharmacology, SUNY Upstate Medical Center, Syracuse, New York 13210

YERACH DASKAL(249),     Department of Pharmacology, Baylor College of Medicine, Houston, Texas 77025

PHILIP DiSALA(411),     Department of Obstetrics and Gynecology, University of California at Irvine, Irvine, California 92717

EVAN B. DOUPLE(125),     Radiobiology Laboratories of the Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire 03755

GARY J. DOYLE(227),     Department of Toxicology, Bristol Laboratories, Division of Bristol-Myers Company, Syracuse, New York 13201

BENJAMIN DREWINKO(37),     Department of Laboratory Medicine, The University of Texas System Cancer Center, M. D. Anderson Hospital, 6723 Bertner Drive, Houston, Texas 77025

JOHN R. DURANT(317),     Director, Comprehensive Cancer Center, University of Alabama in Birmingham, University Station, Birmingham, Alabama 35294

LAWRENCE H. EINHORN(323),     Department of Medicine, Indiana University Medical Center and the Indianapolis Veteran’s Administration Hospital, Indianapolis, Indiana 46223

DAVID ELSON(445),     Department of Medicine, Division of Oncology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78284

RONALD H. ERLICH(305),     Product Development Research, Bristol Laboratories, Division of Bristol-Myers Company, Syracuse, New York 13201

WILLIAM E. EVANS(477),     Department of Pharmacy, St. Jude Children’s Research Hospital, 332 N Lauderdale, Memphis, Tennessee 38101

HADRIAN N.A. FRAVAL(57),     Institute of Cancer Research, Royal Cancer Hospital, Pollards Wood Research Station, Nightingales Lane, Chalfont St. Giles, Buckinghamshire, United Kingdom HP8 4S

MICHAEL A. FRIEDMAN(459),     University of California, Department of Medicine, Cancer Research Institute, San Francisco, California 94143

GLEN GALE(113),     Veterans Administration Hospital, 109 Bee Street, Charleston, South Carolina 29403

JUDITH GOLDBERG(383),     Department of Neoplastic Diseases, Mount Sinai School of Medicine of the City University of New York, Fifth Avenue and East 100 Street, New York, New York 10029

ALPHONSE P. GRANATEK(305),     Research and Development, Bristol Laboratories, Division of Bristol-Myers Company, Syracuse, New York 13201

ALEXANDER A. GREEN(477),     Department of Hematology/Oncology, St. Jude Children’s Research Hospital, 332 N. Lauderdale, Memphis, Tennessee 38101

EZRA M. GREENSPAN(383),     Department of Neoplastic Diseases, Mount Sinai School of Medicine of the City University of New York, Fifth Avenue and East 100 Street, New York, New York 10029

ANTHONY M. GUARINO(237),     Laboratory of...